134 related articles for article (PubMed ID: 38070657)
1. Development and evaluation of C10 and SNAC erodible tablets for gastric delivery of a GIP/GLP1 peptide in monkeys.
Tran H; Dogra M; Huang S; Aihara E; ElSayed M; Aburub A
Int J Pharm; 2024 Jan; 650():123680. PubMed ID: 38070657
[TBL] [Abstract][Full Text] [Related]
2.
Tran H; Aihara E; Mohammed FA; Qu H; Riley A; Su Y; Lai X; Huang S; Aburub A; Chen JJH; Vitale OH; Lao Y; Estwick S; Qi Z; ElSayed MEH
Mol Pharm; 2023 Feb; 20(2):929-941. PubMed ID: 36592951
[TBL] [Abstract][Full Text] [Related]
3. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C
Twarog C; Fattah S; Heade J; Maher S; Fattal E; Brayden DJ
Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30781867
[TBL] [Abstract][Full Text] [Related]
4. Design and Development of a New Glucagon-Like Peptide-1 Receptor Agonist to Obtain High Oral Bioavailability.
Chen H; Lu Y; Shi S; Zhang Q; Cao X; Sun L; An D; Zhang X; Kong X; Liu J
Pharm Res; 2022 Aug; 39(8):1891-1906. PubMed ID: 35698011
[TBL] [Abstract][Full Text] [Related]
5. Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study.
Baekdal TA; Donsmark M; Hartoft-Nielsen ML; Søndergaard FL; Connor A
Clin Pharmacol Drug Dev; 2021 May; 10(5):453-462. PubMed ID: 33750044
[TBL] [Abstract][Full Text] [Related]
6. A head-to-head Caco-2 assay comparison of the mechanisms of action of the intestinal permeation enhancers: SNAC and sodium caprate (C
Twarog C; Liu K; O'Brien PJ; Dawson KA; Fattal E; Illel B; Brayden DJ
Eur J Pharm Biopharm; 2020 Jul; 152():95-107. PubMed ID: 32387703
[TBL] [Abstract][Full Text] [Related]
7. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of the intestinal permeation enhancers, SNAC and sodium caprate (C
Twarog C; McCartney F; Harrison SM; Illel B; Fattal E; Brayden DJ
Eur J Pharm Sci; 2021 Mar; 158():105685. PubMed ID: 33359131
[TBL] [Abstract][Full Text] [Related]
9. Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes.
Granhall C; Donsmark M; Blicher TM; Golor G; Søndergaard FL; Thomsen M; Bækdal TA
Clin Pharmacokinet; 2019 Jun; 58(6):781-791. PubMed ID: 30565096
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C
Twarog C; Fattal E; Noiray M; Illel B; Brayden DJ; Taverna M; Hillaireau H
Int J Pharm; 2022 Oct; 626():122131. PubMed ID: 36028084
[TBL] [Abstract][Full Text] [Related]
11. SNAC for Enhanced Oral Bioavailability: An Updated Review.
Kommineni N; Sainaga Jyothi VGS; Butreddy A; Raju S; Shapira T; Khan W; Angsantikul P; Domb AJ
Pharm Res; 2023 Mar; 40(3):633-650. PubMed ID: 36539668
[TBL] [Abstract][Full Text] [Related]
12. Current Understanding of Sodium N-(8-[2-Hydroxylbenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience.
Solis-Herrera C; Kane MP; Triplitt C
Clin Diabetes; 2024; 42(1):74-86. PubMed ID: 38230324
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal Permeation Enhancers Beyond Sodium Caprate and SNAC - What is Coming Next?
Bohley M; Leroux JC
Adv Sci (Weinh); 2024 Jun; ():e2400843. PubMed ID: 38884149
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects.
Castelli MC; Wong DF; Friedman K; Riley MG
Clin Ther; 2011 Jul; 33(7):934-45. PubMed ID: 21722960
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals.
Kim JC; Park EJ; Na DH
Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559036
[TBL] [Abstract][Full Text] [Related]
16. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.
Buckley ST; Bækdal TA; Vegge A; Maarbjerg SJ; Pyke C; Ahnfelt-Rønne J; Madsen KG; Schéele SG; Alanentalo T; Kirk RK; Pedersen BL; Skyggebjerg RB; Benie AJ; Strauss HM; Wahlund PO; Bjerregaard S; Farkas E; Fekete C; Søndergaard FL; Borregaard J; Hartoft-Nielsen ML; Knudsen LB
Sci Transl Med; 2018 Nov; 10(467):. PubMed ID: 30429357
[TBL] [Abstract][Full Text] [Related]
17. Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
Bækdal TA; Borregaard J; Hansen CW; Thomsen M; Anderson TW
Clin Pharmacokinet; 2019 Sep; 58(9):1193-1203. PubMed ID: 30945118
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Multi-Component Formulation for Intestinal Delivery of a GLP-1/Glucagon Co-agonist Peptide.
Tran H; Patel PJ; Aburub A; Sperry A; Estwick S; ElSayed MEH; -Mannan AD
Pharm Res; 2022 Oct; 39(10):2555-2567. PubMed ID: 36050547
[TBL] [Abstract][Full Text] [Related]
19. Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjects: an open-label, one-sequence crossover, single-center, multiple-dose, two-part trial.
Hauge C; Breitschaft A; Hartoft-Nielsen ML; Jensen S; Bækdal TA
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1139-1148. PubMed ID: 34289755
[TBL] [Abstract][Full Text] [Related]
20. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Aroda VR; Blonde L; Pratley RE
Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
